TIDMCRV

RNS Number : 8446H

Craven House Capital PLC

29 November 2022

Craven House Capital

Annual Results for year ended 31 May 2022

Craven House Capital PLC

29 November 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EU (WITHDRAWAL) ACT 2018.

Craven House Capital plc

("Craven House" or the "Company")

Annual Results for year ended 31 May 2022

CRAVEN HOUSE CAPITAL PLC

CHAIRMAN'S STATEMENT

FOR THE YEARED 31 MAY 2022

 
 
                                                                         Dear Shareholder 
 
                         I am pleased to provide an introduction to the annual report and 
                    financial statements for Craven House Capital Plc for the year ending 
                                                                             31 May 2022. 
 
 
                     Valuations of the four portfolio companies remained unchanged during 
                       the year. Positive progress was demonstrated by each entity during 
                       the year as is detailed further in the Investment Manager's report 
                                                                                   below. 
 
 
 
                                                                               Mark Pajak 
                                                                          Acting Chairman 
 

CRAVEN HOUSE CAPITAL PLC

INVESTMENT MANAGER'S REPORT

FOR THE YEARED 31 MAY 2022

 
 
 

Statement by the Investment Manager

The Company's investment portfolio comprises minority shareholdings in four Swedish-managed businesses operating in the eCommerce and pharmaceutical sector.

The Company's investments are held at fair value in accordance with the IPEVC guidelines. We have used the prior-year valuations as a starting point for estimation of fair value and have applied adequate consideration to current facts and circumstances in reviewing the respective valuations. A summary of the Company's investments is as follows with further information provided in notes 8 and 14 below;

 
 Investment                                  Value at 31        Value at 31 
                                                 May 2022           May 2021 
  Comprising: 
  Shares in Garimon Limited                    $1,600,000         $1,600,000 
  Shares in Rosedog Limited                    $1,600,000         $1,600,000 
  Shares in Honeydog Limited                   $1,600,000         $1,600,000 
  Shares in Bio Vitos Medical Limited          $1,600,000         $1,600,000 
 

Each investee companies demonstrated positive progress during the financial year, however remain at 'pre-revenue' stage of business development. Updated information on each entity is below.

Garimon Limited - 29.9% shareholding

As at end May 2022 Garimon's assets comprised ownership of two domains:

-- www.magazinos.com: a platform for digital magazine distribution, with over 10,000 magazines freely available for readers.

Severe disruption has been experienced in recent months as the domain's servers were hosted in the Ukraine. This has set back plans for fundraising originally planned for early 2022. Management have taken the decision to re-locate the servers and will relaunch the site by the end of 2022. It is anticipated that advertising revenue will begin to be generated in early 2023. The domain will continue to be run with very low overheads.

-- www.onebas.com - is an optimised search engine providing a portal to music content freely circulating online. Considerable development and investment has been made to develop this website during 2022.

As was recently announced and is detailed further in note 17 below, the onebas.com domain was transferred out of Garimon post year-end and into a new entity (Stormfjord Ltd). Stormfjord Ltd has subsequently undertaken two rounds of arms-length financing, (one for $20,000 and the other for $500,000) both of these placing a valuation of $5,000,000 on the domain. The proceeds of this financing have been used to upgrade the functionality and capacity of the websites as well as launch a PR / advertising campaign across key target markets. This PR campaign has so far launched in Norway, Denmark and Italy with very encouraging results.

Further campaigns are schedule for the UK and Germany in November / December 2022 and will continue into new geographies through the course of 2023. Management's goal is to continue to drive daily user grow which will lead to revenue generation though advertising revenue and also via the direct sale of content.

Bio Vitos Medical Limited - 24.5% shareholding

Bio Vitos has two principal assets;

As previously disclosed, during the period Bio Vitos acquired the licence to market a patented heart drug 'Succifer' (also marketed as 'Inofer'), from Double Bond Pharmaceutical AB. The drug has been demonstrated to improve iron uptake in patients with chronic heart conditions.

Bio Vitos is also the owner of a number of dietary / Omega-3 supplement products, marketed under the 'Ocean Skin Lab' brand.

Management are in ongoing negotiations with third parties with a view to finalising sales / distribution agreements for both of these products.

Rosedog Limited - 29.9% shareholder

Rosedog is the owner of TV Zinos (www.tvzinos.com), a website which offers a number of free-to-view television channels. TV Zinos has organically grown its new-use base to over c.20,000 unique users per month. It is therefore anticipated that advertising revenue will begin to be generated in 2023. The domain will continue to be run with very low overheads.

Honeydog Ltd - 29.9% shareholder

During the period Honeydog became the 25% owner of the entity which owns the licence to manufacture and distribute the chemotherapy drug, SI-053 / 'Temodex' which is used in the treatment of brain tumours, offering significant increases in survival rates. The drug is approaching the end of a period of clinical trials, which will mark the last stage of approval required prior to sales and marketing.

Desmond Holdings Ltd

Investment Manager to Craven House Capital Plc

CRAVEN HOUSE CAPITAL PLC

STRATEGIC REPORT

FOR THE YEARED 31 MAY 2022

 
 
 

The directors present the Strategic Report of Craven House Capital plc for the year ended 31 May 2022.

Principal activity

The Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector. The investments or acquisitions may be funded wholly by cash, the issue of new shares or debt, or a mix thereof, as the Board deems appropriate. The Company's equity interest in a proposed investment may range from a minority position to 100% ownership; the proposed investments may be either quoted or unquoted, although will likely be unquoted in the majority of cases. The Company will specifically target investments which the Board believes offer high growth opportunities or steady cash flows and where the exit will be a liquidity event, such as a trade sale or IPO.

Review of the Business in the year

A comprehensive review of the Company's performance and business activities is included in the Investment Manager's Report above. The Company's portfolio comprises minority stakes in four e-commerce businesses which were acquired in March 2020. The status of the underlying investments is disclosed in further detail in notes 8 and 14 below. The only material movement in the Company's balance sheet during the year was the increase in amounts owing to Craven Industrial Holdings Plc in order to satisfy working capital requirements.

Position of the Company's business at the end of the year

Sufficient cash remains available to the Company from its subsidiaries and via external loan facilities to ensure it is able to meet its liabilities as they fall due. Other than directors, the Company has no employees and the majority of overhead expenditure continues to comprise regulatory, accounting and audit costs.

Principal risks and uncertainties facing the business

The principal risks to the business include the ability of the Company to successfully execute its Investing Policy and the early / pre-revenue stage of the development of the current portfolio of investments. Description of these risks are further detailed in note 14 below.

Corporate governance

The directors place a high degree of importance on ensuring that high standards of Corporate Governance are maintained and have therefore chosen to apply the framework as provided by the Quoted Companies Alliance Corporate Governance Code for small and medium size companies (2018) (the 'QCA Code').

Section 172(1) statement

The directors have acted in a way that they have considered, in good faith, to be most likely to promote the success of Craven House Capital Plc for the benefit of its members, and in doing so had regard, amongst other matters to:

   --           the likely consequences of any decision in the long-term; 
   --           the Company has no employees; 

-- the need to foster the Company's business relationships with suppliers, customers and others;

   --           the impact of the Company's operations on the community and the environment; 

-- the desirability of the Company's maintaining a reputation for high standards of business conduct;

   --           and to act fairly between members of the Company 

The directors also took into account the views and interests of a wider set of stakeholders, the Government and non-government organisations.

Section 172(1) statement - continued

Considering the broad range of interests in the Company is an important part of the way the Board makes decisions; however, in balancing those different perspectives, it won't always be possible to deliver everyone's desired outcome.

How does the Board engage with stakeholders?

The Board engages with its stakeholders in a number of pre-planned ways, these include; review meetings with our brokers and advisors, shareholders have the ability to email the Company directly and the Board will reply to questions within the regulatory limits, the Company issues both RNS Reach and RNS communications on a regular basis and the Company's web site is continuously updated to inform our stakeholders. The Company's annual report is also an opportunity to update our stakeholders.

The Board has also adopted a code of conduct and follows specific guidance on all governance requirements which are regularly reviewed with its advisors to ensure full compliance.

The Board considers and discusses information from across the organisation to help it understand the impact of its operations, and the interests and views of our key stakeholders.

As a result of these activities, the Board has an overview of engagement with stakeholders, and other relevant factors, which enables the directors to comply with their legal duty under section 172 of the Companies Act 2006.

Due to the nature of the Company, no decisions were made by the directors during the reporting period which required them to have regard to the matters set out in section 172 of the Companies Act 2006.

Mr M J Pajak - Director of behalf of the Board

CRAVEN HOUSE CAPITAL PLC

REPORT OF THE DIRECTORS

FOR THE YEARED 31 MAY 2022

 
 
 

The directors present their annual report with the audited financial statements of the Company for the year ended 31 May 2022.

DIVIDS

No dividends have been declared for the year ended 31 May 2022.

EVENTS SINCE THE OF THE YEAR

Information relating to events since the end of the year is given in the note 17 to the financial statements.

DIRECTORS

The directors who held office during the year were:

Mr M J Pajak;

Mr B S Bindra; and

Mr C P Morrison.

Directors' remuneration and details of service contracts are given in note 3 to the financial statements.

POLITICAL AND CHARITABLE CONTRIBUTIONS

No charitable or political donations were made during the year.

FINANCIAL RISK MANAGEMENT POLICIES

Information on the use of financial instruments by the Company and its management of financial risk is disclosed in note 14 to the financial statements.

FUTURE DEVELOPMENTS

In the coming year the Company will continue to execute its investment strategy. Details of post year end transactions are disclosed in note 17.

SIGNIFICANT SHAREHOLDERS

Shareholders with holdings of more than 3% of the Company as of the date of this report are as follows;

Jim Nominees Ltd - 7.9%

Vidacos Nominees Ltd - 16.9%

Interactive Brokers LLC - 11.7%

WB Nominees Ltd - 22.8%

HSBC Global Custody Nominee (UK) Ltd - 8.4%

DIRECTOR SHAREHOLDINGS

Shareholdings in the Company by directors as of the date of this report are as follows;

Mr M J Pajak indirect holdings (via Desmond Holdings Ltd) - 272,705 ordinary shares of $1.00

Mr B S Bindra - 14,440 ordinary shares of $1.00

Mr C P Morrison - 7,356 ordinary shares of $1.00

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with International Financial Reporting Standards, UK adopted international standards and applicable law. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company, and of the profit or loss for that period. In preparing these financial statements, the directors are required to:

 
-  select suitable accounting policies and then apply them consistently; 
-  make judgements and accounting estimates that are reasonable 
    and prudent; 
-  state whether applicable accounting standards have been followed, 
    subject to any material departures disclosed and explained in 
    the financial statements; 
-  prepare the financial statements on the going concern basis unless 
    it is inappropriate to presume that the Company will continue 
    in business. 
 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the Company's website. Legislation in the United Kingdom governing the preparation and dissemination of the accounts and the other information included in annual reports may differ from legislation in other jurisdictions.

The Company is compliant with AIM Rule 26 regarding the Company's website.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the Company's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the Company's auditors are aware of that information.

AUDITOR

A resolution for the re-appointment of Edwards Veeder (UK) Limited, Chartered Accountants & Business Advisors will be proposed in accordance with Section 489 of the Companies Act 2006 at the forthcoming Annual General Meeting.

Mr M J Pajak - Director of behalf of the Board

INDEPENT AUDITOR'S REPORT TO THE MEMBERS OF

CRAVEN HOUSE CAPITAL PLC

 
 
 

Opinion

We have audited the financial statements of Craven House Capital Plc (the 'company') for the year ended 31 May 2022 which comprise the statement of comprehensive income, the statement of financial position, the statement of changes in equity, the statement of cash flows and the related notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and UK adopted international standards.

In our opinion, the financial statements:

-- give a true and fair view of the state of the company's affairs as at 31 May 2022 and of its loss for the

year then ended;

-- have been properly prepared in accordance with UK adopted international standards; and

   --              have been prepared in accordance with the requirements of the Companies Act 2006. 

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities are described below. We have fulfilled our ethical responsibilities under, and are independent of the company in accordance with, UK ethical requirements including the FRC Ethical Standard. We believe that the audit evidence we have obtained is a sufficient and appropriate basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report

.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period and include the most significant assessed risks of material misstatement (whether or not due to fraud) we identified, including those which had the greatest effect on: the overall audit strategy, the allocation of resources in the audit; and directing the efforts of the engagement team. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

 
 Key audit matters               Description                How the scope of our audit 
                                  of risk                    addressed the risk 
 Investment valuation 
 
 For the financial year            The company's             Our audit work included but 
 ended 31 May 2022,                assessment of             was not restricted to: 
 investments                       the valuation 
 measured at fair value            of investments             *    We reviewed the high level controls in operation in 
 amounted to $6,400,000            measured at fair                relation to investment valuations; 
 which represents 99% of           value requires 
 total assets.                     significant judgement. 
                                -------------------------  ----------------------------------------------------------- 
 
 
 
 
 
       Key audit     Description     How the scope of our 
        matters       of risk          audit addressed the 
                                       risk 
        Investment 
        valuation 
        (continued)                     *    We considered if the company's valuation policy is in 
                      There is a             line with The International Private Equity and 
        The           risk that              Venture Capital Valuation (IPEV) guidelines and UK 
        valuation     the                    adopted international standards; 
        of            application 
        investments   of an 
        is            inappropriate 
        considered    valuation         *    We reviewed and critically challenged the 
        a key         methodology            reasonableness of the assumptions applied in the 
        audit         and/or the             investment managers' valuation memo for the financial 
        matter as     use of                 year ended 31 May 2022; 
        investments   inappropriate 
        represent     assumptions 
        significant   could result 
        balances on   in the 
        the           valuation of 
        statement     investments 
        of            being 
        financial     materially 
        position.     misstated as 
                      at 31 May 
                      2022. 
                     --------------  ---------------------------------------------------------------------- 
        Investment                               Our audit work included 
        ownership                                but was not restricted 
        and                                      to: 
        existence     There is a 
                      risk that                   *    Shareholder registers were reviewed to confirm the 
        The           the company                      shares were held by the company; 
        ownership     does not 
        and           own the 
        existence     rights to the 
        of            investments                 *    Shareholder and purchase agreements were reviewed to 
        investments   or that                          establish ownership; 
        are           the 
        considered    investments 
        a key audit   do not 
        matter as     exist at the                *    Checked the ownership title of investments held in 
        investments   year ended                       the associate company 
        represent     31 May 2022. 
        99% of 
        total 
        assets 
        on the 
        statement 
        of 
        financial 
        position. 
                     --------------  ---------------------------------------------------------------------- 
        Management                         Our audit work included 
        override                            but was not restricted 
        of controls                         to 
                      There is a 
        We are        risk that              *    We have considered the controls in place, remained 
        required to   management                  alert for material and unusual items and tested a 
        consider      may override                sample of journals to assess the risk. 
        how           the controls 
        management    to suit 
        biases        their 
        could         objectives. 
        affect the 
        results 
        of the 
        company. 
                     --------------  ---------------------------------------------------------------------- 
 
       This is not a complete list of all risks identified by our audit. 
 
 
 
 
 
 
       Our application of materiality 
       We apply the concept of materiality both in planning and performing 
       our audit and in evaluating the effect of misstatements. We consider 
       materiality to be the magnitude by which misstatements, including 
       omissions could influence the economic decisions of reasonable users 
       that are taken on the basis of the financial statements. Importantly, 
       misstatements below these levels will not necessarily be evaluated 
       as material, as we also take into account the nature of identified 
       misstatements, and the particular circumstances of their occurrence, 
       when evaluating their effect on the financial statements as a whole. 
       Based on our professional judgement, we determined the materiality 
       for the financial statements as a whole to be $97,000 which is based 
       on 1.5% of total assets. We considered this as an appropriate benchmark. 
       We set performance materiality as 80% of the overall Financial Statement 
       materiality. 
       We report to the Audit Committee all identified unadjusted errors 
       in excess of $4,850 which is set at 5% of planning materiality. Errors 
       below that threshold would also be reported if, in our opinion as 
       auditor, disclosure was required on qualitative grounds. 
 
       An overview of the scope of our audit 
       Our audit was scoped by obtaining an understanding of the company 
       and its environment, including controls and assessing the risks of 
       material misstatements. 
 
       We carried out a full scope audit of the company's financial statements. 
       This included specific audit procedures where the extent of our audit 
       work was based on our assessment of the risks of material misstatement. 
 
       All audit work to respond to the risks of material misstatement were 
       performed directly by the audit engagement team. We set out the key 
       audit matters that had the greatest impact on our audit strategy and 
       scope within the key audit matters section. 
 
       Other information 
       The other information comprises the information included in the Chairman's 
       Statement, the Investment Manager's Report, the Strategic Report and 
       the Report of the Directors. The directors are responsible for the 
       other information. Our opinion on the financial statements does not 
       cover the other information and, except to the extent otherwise explicitly 
       stated in our report, we do not express any form of assurance conclusion 
       thereon. 
 
       In connection with our audit of the financial statements, our responsibility 
       is to read the other information and, in doing so, consider whether 
       the other information is materially inconsistent with the financial 
       statements or our knowledge obtained in the audit or otherwise appears 
       to be materially misstated. If we identify such material inconsistencies 
       or apparent material misstatements, we are required to determine whether 
       there is a material misstatement in the financial statements or a 
       material misstatement of the other information. If, based on the work 
       we have performed, we conclude that there is a material misstatement 
       of this other information, we are required to report that fact. 
 
       We have nothing to report in this regard. 
 
       Opinions on other matters prescribed by the Companies Act 2006 
       In our opinion, based on the work undertaken in the course of the 
       audit: 
        *    the information given in the Strategic Report and the 
             Report of the Directors for the financial year for 
             which the financial statements are prepared is 
             consistent with the financial statements; and 
 
 
        *    the Strategic Report and the Report of the Directors 
             have been prepared in accordance with applicable 
             legal requirements. 
 
 
 
 
 
 
 
 
       Matters on which we are required to report by exception 
       In the light of the knowledge and understanding of the company and 
       its environment obtained in the course of the audit, we have not identified 
       material misstatements in the Strategic Report or the Report of the 
       Directors. 
 
       We have nothing to report in respect of the following matters in relation 
       to which the Companies Act 2006 requires us to report to you if, in 
       our opinion: 
 
        *    adequate accounting records have not been kept, or 
             returns adequate for our audit have not been received 
             from branches not visited by us; or 
 
 
        *    the financial statements are not in agreement with 
             the accounting records and returns; or 
 
 
        *    certain disclosures of directors' remuneration 
             specified by law are not made; or 
 
 
        *    we have not received all the information and 
             explanations we require for our audit. 
 
 
 
       Responsibilities of directors 
       As explained more fully in the Statement of Directors' Responsibilities 
       set out on page 8 the directors are responsible for the preparation 
       of the financial statements and for being satisfied that they give 
       a true and fair view, and for such internal control as the directors 
       determine is necessary to enable the preparation of financial statements 
       that are free from material misstatement, whether due to fraud or 
       error. 
 
       In preparing the financial statements, the directors are responsible 
       for assessing the company's ability to continue as a going concern, 
       disclosing, as applicable, matters related to going concern and using 
       the going concern basis of accounting unless the directors either 
       intend to liquidate the company or to cease operations, or have no 
       realistic alternative but to do so. 
 
       Auditor's responsibilities for the audit of the financial statements 
       Our objectives are to obtain reasonable assurance about whether the 
       financial statements as a whole are free from material misstatement, 
       whether due to fraud or error, and to issue an auditor's report that 
       includes our opinion. Reasonable assurance is a high level of assurance, 
       but is not a guarantee that an audit conducted in accordance with 
       ISAs (UK) will always detect a material misstatement when it exists. 
       Misstatements can arise from fraud or error and are considered material 
       if, individually or in the aggregate, they could reasonably be expected 
       to influence the economic decisions of users taken on the basis of 
       these financial statements. 
 
       Irregularities, including fraud, are instances of non-compliance with 
       laws and regulations. We design procedures in line with our responsibilities, 
       outlined above, to detect material misstatements in respect of irregularities, 
       including fraud. The extent to which our procedures are capable of 
       detecting irregularities, including fraud is detailed below: 
 
        *    Enquiries with management, about any known or 
             suspected instances of non-compliance with laws and 
             regulations and fraud. 
 
 
        *    Auditing the risk of management of override controls, 
             including through testing journal entries and other 
             adjustments for appropriateness. 
 
 
        *    Challenging assumptions and judgments made by 
             management in their significant accounting estimates. 
 
 
       Because of the field in which the client operates, we identified that 
       employment law, LSE listing rules and compliance with the Companies 
       Act 2006 are most likely to have a material impact on the financial 
       statements. 
 
       The group is subject to many other laws and regulations where consequences 
       of non-compliance could have material effect on amounts or disclosures 
       in the financial statements, for instance through the imposition of 
       fines. We identified the following areas as most likely to have such 
       an effect: The Listing Rules in certain aspects of company legislation 
       recognising the financial and regulated nature of the Company's activities 
       and its legal form. Auditing standards limit required audit procedure 
       to identify non-compliance with these laws and regulations to inquiry 
       of the directors and other management and inspection of regulatory 
       and legal correspondence, if any. Through these procedures, we did 
       not become aware of actual or suspected non-compliance. 
 
       Owing to the inherent limitations of an audit, there's an unavoidable 
       risk that some material misstatements in the financial statements 
       may not be detected, even though the audit is properly planned and 
       performed in accordance with ISAs (UK). For instance, the further 
       removed non-compliances from the events and transactions reflected 
       in the financial statements, the less likely the auditor is to become 
       aware of it or to recognise the non-compliance. 
 
 
       A further description of our responsibilities for the audit of the 
       financial statements is located on the Financial Reporting Council's 
       website at: https://www.frc.org.uk/auditorsresponsibilities . This 
       description forms part of our auditor's report. 
 
       Use of our report 
       This report is made solely to the company's members, as a body, in 
       accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our 
       audit work has been undertaken so that we might state to the company's 
       members those matters we are required to state to them in an auditor's 
       report and for no other purpose. To the fullest extent permitted by 
       law, we do not accept or assume responsibility to anyone other than 
       the company and the company's members as a body, for our audit work, 
       for this report, or for the opinions we have formed. 
 
 
       Lee Lederberg 
 
 
       Senior Statutory Auditor 
       for and on behalf of Edwards Veeder (UK) Limited 
       Chartered Accountants & Statutory Audit Firm 
       Ground Floor, 4 Broadgate, 
       Broadway Business Park, 
       Chadderton, 
       Greater Manchester, 
       United Kiingdom, 
       OL9 9XA 
 

CRAVEN HOUSE CAPITAL PLC

STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEARED 31 MAY 2022

 
 
 
 
 
 
 
                                            2022         2021 
                                Notes      $'000        $'000 
 
 CONTINUING OPERATIONS 
 
   Changes in fair value                       -      (1,600) 
 
 Administrative expenses                   (180)        (208) 
 
   Exceptional costs               4           -        (623) 
                                       ---------   ---------- 
 
                                           (180)      (2,431) 
   OPERATING LOSS 
                                            (56)            - 
   Interest expense 
 
   LOSS BEFORE INCOME TAX          5       (236)      (2,431) 
 
 Income tax                       6            -            - 
                                       ---------   ---------- 
 
 LOSS FOR THE YEAR AND TOTAL 
  COMPREHENSIVE INCOME                     (236)      (2,431) 
                                       =========   ========== 
 
 
 Loss per share expressed 
 in cents per share: 
 Basic and diluted                7       (6.11)      (62.92) 
 
 
 

The notes on pages 18 to 35 form part of the financial statements.

                CRAVEN HOUSE CAPITAL PLC                                                  Company Number 05123368 

STATEMENT OF FINANCIAL POSITION

AS AT 31 MAY 2022

 
 
 
 
 
                                           2022      2021 
                                Notes     $'000     $'000 
 ASSETS 
 NON-CURRENT ASSETS 
 Investments at fair 
  value through 
 profit or loss                     8     6,400     6,400 
                                       --------  -------- 
                                          6,400     6,400 
                                       --------  -------- 
 
 CURRENT ASSETS 
 Trade and other receivables        9        43        38 
 Cash and cash equivalents         10         1         5 
                                       --------  -------- 
                                             44        43 
                                       --------  -------- 
 TOTAL ASSETS                             6,444     6,443 
                                       ========  ======== 
 
 
 EQUITY 
 SHAREHOLDERS' EQUITY 
 Called up share capital           11     3,802     3,802 
 Share premium                           11,153    11,153 
 Accumulated deficit                    (9,824)   (9,588) 
                                       --------  -------- 
 TOTAL EQUITY                             5,131     5,367 
                                       --------  -------- 
 
 LIABILITIES 
 CURRENT LIABILITIES 
 Trade and other payables          12        76        87 
  NON-CURRENT LIABILITES 
  Other payables                   13     1,237       989 
 TOTAL LIABILITIES                        1,313     1,076 
                                       --------  -------- 
 
 TOTAL EQUITY AND LIABILITIES             6,444     6,443 
                                       ========  ======== 
 
 

Approved and authorised for issue by the Board on ......................2022 and signed on its behalf by:

.................................................................

Mr M J Pajak - Director

The notes on pages 18 to 35 form part of the financial statements.

CRAVEN HOUSE CAPITAL PLC

STATEMENT OF CHANGES IN EQUITY

FOR THE YEARED 31 MAY 2022

 
 
    The notes on pages 18 to 35 form part of the financial statements. 
 
 
 
 
                                Called       Share         Accumulated 
                              up share     premium             deficit     Total 
                               capital       $'000               $'000     $'000 
                                 $'000 
 
 Balance at 1 June 
  2020                           3,802      11,153             (7,157)     7,798 
 
 Changes in equity 
 Issue of share capital              -           -                   -         - 
                            ----------  ----------      --------------  -------- 
 Transactions with owners        3,802      11,153             (7,157)     7,798 
                            ----------  ----------      --------------  -------- 
 
 Loss for the year                   -           -             (2,431)   (2,431) 
 
 Balance at 31 May 
  2021                           3,802      11,153             (9,588)     5,367 
                            ----------  ----------      --------------  -------- 
 
 Changes in equity 
 Issue of share capital              -           -                   -         - 
                            ----------  ----------      --------------  -------- 
 Transactions with owners        3,802      11,153             (9,588)     5,367 
                            ----------  ----------      --------------  -------- 
 
 Loss for the year                   -           -               (236)     (236) 
                            ----------  ----------      --------------  -------- 
 
 Balance at 31 May 
  2022                           3,802      11,153             (9,824)     5,131 
                            ----------  ----------      --------------  -------- 
 
 

CRAVEN HOUSE CAPITAL PLC

STATEMENT OF CASH FLOWS

FOR THE YEARED 31 MAY 2022

 
 
 
                                                                          2022          2021 
                                                           Notes         $'000         $'000 
 
 Cash flows from operating activities 
 Loss before income tax                                                  (236)       (2,431) 
 Adjustments for non-cash items 
 Fair value movement arising on investments                                  -         1,600 
 (Increase)/decrease in trade and 
  other receivables                                                        (5)             8 
 Decrease in trade and other payables                                     (11)         (167) 
  Interest expense                                                          56             - 
 Net cash outflow from operating 
  activities                                                             (196)         (990) 
 
 Cash flows from financing activities 
  Loans received                                                           192           989 
  Net cash inflow from financing 
  activities                                                               192           989 
                                                                        ------      -------- 
 
 
   Net decrease in cash and cash equivalents                               (4)           (1) 
 
 Cash and cash equivalents at the 
  beginning 
 of the year                                               10                5             6 
 
 Cash and cash equivalents at the 
  end of the year                                          10                1             5 
                                                                        ======      ======== 
 
 
 
 
 
 
                   The notes on pages 18 to 35 form part of the financial statements. 
 
 

CRAVEN HOUSE CAPITAL PLC

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEARED 31 MAY 2022

 
 
 
             1. ACCOUNTING POLICIES 
 
             Basis of preparation 
             These financial statements have been prepared in accordance with International 
             Financial Reporting Standards and IFRIC interpretations and with those 
             parts of the Companies Act 2006 applicable to companies reporting under 
             UK adopted international standards. 
 
             Craven House Capital plc is a public company incorporated in the United 
             Kingdom under the Companies Act 2006. The address of the registered office 
             is given on the company information page. The Company is listed on the 
             AIM Market of the London Stock Exchange (ticker: CRV). 
 
             The directors have considered the definition of an investment entity in 
             IFRS 10 as well as the associated application guidance. The directors 
             consider that the Company has met the definition of an investment entity. 
             The significant judgments and assumptions made by the directors in determining 
             that the Company is an investment entity are that; it has obtained funds 
             from investors (its shareholders) and is providing those investors with 
             investment management services; it commits to its investors that its business 
             purpose is to invest funds solely for returns from capital appreciation, 
             investment income, or both; and it measures and evaluates the performance 
             of substantially all of its investments on a fair value basis. 
 
             The main accounting implications for the preparation of the accounts as 
             an investment entity are that the accounts are not prepared on a consolidated 
             basis. Instead the Company's investments in its subsidiaries are accounted 
             for at fair value through its profit and loss account. 
 
             The financial statements have been prepared under the historical cost 
             convention, except to the extent varied below for fair value adjustments 
             required by accounting standards, and in accordance with applicable UK 
             adopted international standards. The principal accounting policies are 
             set out below. 
 
             The financial statements are presented in US dollars which is the Company's 
             functional currency. Amounts are rounded to the nearest thousand, unless 
             otherwise stated. 
 
             Going concern 
             The Company's business activities, together with the factors likely to 
             affect its future development, performance and position are set out in 
             the Investment Manager's Report. The financial statements include the 
             Company's objectives, policies and processes for managing its capital; 
             its financial risk management objectives; details of its financial instruments; 
             and its exposures to credit risk and liquidity risk. The directors believe 
             that the Company is well placed to manage its business risks successfully. 
             The directors have a reasonable expectation that the Company has adequate 
             resources to continue in operational existence for the foreseeable future. 
             Thus they continue to adopt the going concern basis of accounting in preparing 
             the annual financial statements. 
 
             The Company maintains minimal cash reserves, however in addition to the 
             cash on the Company's statement of financial position, sufficient cash 
             is available to the Company via credit facilities to ensure it is able 
             to meet its liabilities as they fall due and there is therefore no risk 
             to the going concern status of the Company. 
 
             There are currently no commitments to provide support to any subsidiary, 
             however the Company may elect to provide capital to its subsidiaries at 
             any time to further its stated Investing Policy. 
 
   1.            ACCOUNTING POLICIES - continued 

The Company has applied for the first time certain amendments to the standards

Amendments to IFRS 4: Insurance Contracts - deferral of IFRS 9 (effective for annual periods beginning on or after 1 January 2021, endorsed by the European Union on 15 December 2020).

Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16: Interest Rate Benchmark Reform - Phase 2 (effective for annual periods beginning on or after 1 January 2021, endorsed by the European Union on 13 January 2021).

Amendments to IFRS 3: Business Combinations; IAS 16: Property, Plant and Equipment; IAS 37: Provisions, Contingent Liabilities and Contingent Assets; and Annual Improvements 2018-2020 (effective for annual periods beginning on or after 1 January 2022, endorsed by the European Union on 28 June 2021).

Amendments to IFRS 16 Leases: Covid-19- Related Rent Concessions beyond 30 June 2021 (effective for annual periods beginning on or after 1 April 202, endorsed by the European Union on 30 August 2021).

None of these amendments have had an effect on the Company's financial position and performance.

The following new and revised standards and interpretations have not been adopted by the Company, whether endorsed by the European Union or not

Amendments to IFRS 17 Insurance Contracts (effective for annual periods beginning on or after 1 January 2023, endorsed by the European Union on 19 November 2021).

Amendments to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (effective for annual periods beginning on or after 1 January 2023, endorsed by the European Union on 2 March 2022).

Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2: Disclosure of Accounting policies (effective for annual periods beginning on or after 1 January 2023, endorsed by the European Union on 2 March 2022).

Amendments to IFRS 17 Insurance Contracts: Initial Application of IFRS 17 and IFRS 9 - Comparative Information (effective for annual periods beginning on or after 1 January 2023, not yet endorsed by the European Union).

Amendments to IAS 12 Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction (effective for annual periods beginning on or after 1 January 2023, not yet endorsed by the European Union).

Amendments to IAS1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current (effective for annual periods beginning on or after 1 January 2023, not yet endorsed by the European Union).

The Company has assessed the impact of the adoption of these standards and interpretations on its financial statements on initial adoption and do not expect these standards to have a material impact.

   1.            ACCOUNTING POLICIES - continued 

Financial assets

Purchases or sales of financial assets are recognised at the date of the transaction. Where appropriate criteria are met, the Company makes use of the option of measuring non current investments upon initial recognition as financial assets at fair value through profit or loss. These criteria include that the fixed asset investment should meet the Company's published Investing Policy and form part of the Company's managed portfolio or similar investments. Such financial assets are carried at fair value and movements in fair value are recognised through profit and loss. For quoted securities, fair value is either the bid price or the last traded price, depending on the convention of the exchange on which the investment is quoted.

Impairment of financial assets

A financial asset not classified at fair value through profit or loss is assessed at each reporting date to determine whether there is objective evidence that it is impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably.

The new impairment model requires forward looking information, which is based on assumptions for the future movement of different economic drivers and how these drivers will affect each other. It also requires management to assign probability to various categories of receivables. Probability of default constitutes a key input in measuring an ECL and entails considerable judgment; it is an estimate of the likelihood of default over a given time horizon, the calculation of which includes historical data, assumptions and expectation of future conditions.

The directors have determined that the application of IFRS 9's impairment requirements does not have a material impact on the financial statements.

ACCOUNTING POLICIES - continued

Measurement

Financial assets at fair value through profit or loss are initially recognised at fair value. Transaction costs are expensed through profit and loss. Subsequent to initial recognition, all financial assets at fair value through profit or loss are measured at fair value in accordance with International Private Equity and Venture Capital Valuation ("IPEVCV") guidelines, as the Company's business is to invest in financial assets with a view to profiting from their total return in the form of capital growth and income. Gains and losses arising from changes in the fair value of the financial assets at fair value through profit or loss are presented in the year in which they arise.

Valuation of investments

A number of the Company's assets are measured at fair value for financial reporting purposes. The Investment Manager determines the appropriate valuation techniques and inputs for fair value measurements.

In estimating the fair value of an asset, the Investment Manager uses market-observable data to the extent it is available. The Investment Manager reports its findings to the Board of Directors of the Company every quarter to explain the cause of fluctuations in the fair value of the assets.

Information about the valuation techniques and inputs used in determining the fair value of various assets and liabilities are disclosed in notes 8 and 14.

Financial instruments that are measured subsequent to initial recognition at fair value are grouped into Levels 1 to 3 based on the degree to which the fair value is observable:

Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 fair value measurements for those derived from inputs other than quoted prices included within Level 1 that are observable for the assets or liability, either directly or indirectly; and Level 3 fair value measurements are those derived from inputs that are not based on observable market data.

   a)           Quoted investments 

Where investments are quoted on recognised stock markets and an active market in the shares exists, the company values those investments at closing mid-market price on the reporting date. Where an active market does not exist those quoted investments are valued by the application of an appropriate valuation methodology as if the relevant investment was unquoted.

   b)        Unquoted investments 

In estimating the fair value for an unquoted investment, the Company applies a methodology that is appropriate in light of the nature, facts and circumstances of the investment and its materiality in the context of the total investment portfolio using reasonable data, market inputs, assumptions and estimates. Any changes in the above data, market inputs, assumptions and estimates will affect the fair value of an investment.

Financial liabilities and equity

Financial liabilities are recognised when the Company becomes party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted for transaction costs. Financial liabilities are measured subsequently at amortised cost using the effective interest method.

An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all its liabilities.

In accordance with IFRIC 19, when a financial liability is extinguished by the issue of equity, the equity instrument issued is measured at fair value and any difference between the financial liability extinguished and the measurement of the equity instrument is recognised in profit and loss.

   1.       ACCOUNTING POLICIES - continued 

Current and deferred tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have enacted by the statement of financial position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date where transactions or events that result in an obligation to pay more tax in the future or a right to pay less tax in the future have occurred at the statement of financial position date. Timing differences between the Company's taxable profits and its results as stated in the financial information that arises from the inclusion of gains and losses in tax assessments in periods different from those in which they are recognised in the financial information.

A deferred tax asset is only recognised for an unused tax loss carried forward if it is considered probable that there will be sufficient future taxable profits against which the loss can be utilised.

Foreign currencies

In preparing the financial statements of the Company, transactions in currencies other than the entity's functional currency are recorded at the rates of exchange prevailing at the dates of the transactions. At each statement of financial position date, monetary items denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences are recognised in profit or loss in the period in which they arise except for exchange differences on monetary items receivable from or payable to a foreign operation for which settlement is neither planned nor likely to occur; which form part of the net investment in a foreign operation and which are recognised in the foreign currency translation reserve.

For the purposes of presenting US dollar financial statements, the assets and liabilities of the Company's foreign operations are expressed using exchange rates prevailing at the statement of financial position date. Income and expense items are translated at the average exchange rate for the period, unless exchange rates fluctuated significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are classified as equity and recognised in a foreign currency translation reserve.

Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the directors. The directors, who are responsible for allocating resources and assessing performance of the operating segments, have been identified as the senior management that make strategic decisions.

Critical accounting estimates and judgements

Preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Further information regarding the assumptions relied upon and sensitivity analysis around these assumptions is provided in note 14 below.

In particular, significant areas of estimation, uncertainty and critical judgements in applying accounting policies that have the most significant effect on the amount recognised in the financial statements relate to the valuation of investments.

   1.       ACCOUNTING POLICIES - continued 

Critical accounting estimates and judgements - continued

The Company has made a number of investments in the form of equity instruments in private companies operating in emerging markets. The investee companies are generally at a key stage in their development and operating in an environment of uncertainty in capital markets. Should planned development prove successful, the value of the Company's investment is likely to increase, although there can be no guarantee that this will be the case. Should planned development prove unsuccessful, there is a material risk that the Company's investments may be impaired. The carrying amounts of investments are therefore highly sensitive to the assumption that the strategies of these investee companies will be successfully executed.

The directors have also determined that the Company meets IFRS 10's definition of an investment company and that the functional currency is appropriate given that underlying transactions, events and conditions that are most likely to impact on the Company's performance are more closely linked to the US dollar than GB sterling.

Share capital and share premium

Share capital represents the nominal (par) value of shares that have been issued.

Share premium includes any premium received on issue of share capital. Any transaction costs associated with the issuing of shares are deducted from share premium.

                2.       SEGMENTAL REPORTING 

The operating segment has been determined and reviewed by the directors to be used to make strategic decisions. The directors consider there to be a single business segment being that of investing activities, therefore there is only one reportable segment.

                3.       EMPLOYEES AND DIRECTORS 
 
                                                   2022      2021 
                                                  $'000     $'000 
 Wages and salaries - directors' remuneration         -         - 
                                                 ======    ====== 
 
 

The average monthly number of employees (including directors) during the year was as follows:

 
               2022   2021 
 Directors        3      3 
              =====  ===== 
 

The Company has no employees other than the directors.

    3.        EMPLOYEES AND DIRECTORS - continued 

The service contracts of the directors who served during the year are as follows:

 
                    Basic annual fee 
Mr M J Pajak        $nil 
Mr B S Bindra       $5,000** 
 Mr C P Morrison     $5,000** 
 

** Payable in new ordinary shares of the company at $1.00 per share and issued on a bi-annual basis.

Desmond Holdings Ltd is the Company's Investment Manager. The directors are the key management of the Company. There were no directors (2021: none) to whom retirement benefits were accruing under money purchase schemes.

                4.       EXCEPTIONAL COSTS 

Exceptional costs represent one-off legal expenses incurred during the prior year of $623,076.

                5.        LOSS BEFORE INCOME TAX 

The loss before income tax is stated after charging:

 
                                             2022    2021 
                                            $'000   $'000 
 Rental charges                                 -      17 
 Fees payable to the Company's auditor 
  for the audit of the Company's annual 
  accounts                                     17      17 
 
 
 
 
           6.      INCOME TAX 

Analysis of charge in the year

 
                                         2022      2021 
                                        $'000     $'000 
 Current tax:                               -         - 
 Deferred tax                               -         - 
 
 Tax on loss on ordinary activities         -         - 
                                       ======    ====== 
 
 
 
                                         2022      2021 
                                        $'000     $'000 
 Loss on ordinary activities before 
  tax                                   (236)   (2,431) 
                                       ======  ======== 
 

Analysis of charge in the year

 
 
                                                  2022          2021 
                                                 $'000         $'000 
 Loss on ordinary activities multiplied 
  by the Company's rate of corporation 
  tax in the UK of 19% (2021: 19%)                (45)         (462) 
 
 Effects of: 
 Investment valuation                                -           304 
  Losses carried forward                            45           158 
                                               -------      -------- 
 Current tax charge for the year                     -             - 
  as above 
                                               =======      ======== 
 
 

At 31 May 2022, the Company had UK tax losses of $5,488,630 (2021: $5,978,254) available to be carried forward and utilised against future taxable profits. A deferred tax asset of $1,251,839 (2021: $1,135,868) has not been recognised due to uncertainties over the timing of when taxable profits will arise.

   7.           EARNINGS PER SHARE 

Basic earnings per share is calculated by dividing the earnings attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period.

Diluted earnings per share has not been disclosed as the inclusion of the unexercised warrants would be non-dilutive.

   7.        EARNINGS PER SHARE - continued 

Reconciliations are set out below.

 
                                               2022 
                              Earnings   Weighted average    Per-share amount 
                                $'000     number of shares         cents 
 Basic EPS 
 Earning attributable 
  to ordinary shareholders      (236)         3,863,590            (6.11) 
 
 
 
                                                2021 
                              Earnings    Weighted average    Per-share amount 
                                $'000      number of shares         cents 
 Basic EPS 
 Earning attributable 
  to ordinary shareholders      (2,431)        3,863,590           (62.92) 
 
 
8.  INVESTMENTS 
 
     Investments at fair value through profit or loss 
 

The Company adopted the valuation methodology prescribed in the IPEVCV guidelines to value its investments at fair value through profit and loss.

The Company had the following holdings at 31 May 2022:

 
                                         Principal Place    Ownership 
 Name                         Holding       of Business      Interest 
 
 Garimon Limited               Direct      UK / Sweden        29.9% 
 Honeydog Limited              Direct      UK / Sweden        29.9% 
 Rosedog Limited               Direct      UK / Sweden        29.9% 
 Bio Vitos Medical Limited     Direct      UK / Sweden        24.5% 
 
 
 
 
8.  INVESTMENTS -continued 
 

Investments at fair value through profit or loss

 
                                            Quoted               Unquoted 
                                equity investments     equity investments 
                                             $'000                  $'000       Total 
                                                                                $'000 
 
 At 1 June 2020                                   -                  8,000       8,000 
 
   Fair value movement                            -                (1,600)     (1,600) 
                                 ------------------   --------------------  ---------- 
 At 31 May 2021                                   -                  6,400       6,400 
                                 ------------------   --------------------  ---------- 
 
   Fair value movement                           -                      -           - 
                             ---------------------   --------------------  ---------- 
 At 31 May 2022                                   -                  6,400       6,400 
                                 ------------------   --------------------  ---------- 
 
 
 

The value of Investments at 31 May 2022 represents the Company's acquisitions during 2020 of interests in the above-named four UK entities. These are all unquoted investments and have therefore been measured on a Level 3 basis as no observable market data is available. Further information on each investment holding is as follows;

Shares in Garimon Limited are valued at $1,600,000 representing a 29.9% holding. The valuation of this shareholding is supported by arms-length financing which occurred during and after the end of the period and represents the best indication of the fair value at the year end. Garimon Limited is the owner of "Magazinos.com", an on-line media magazine and periodical content provision service, and www.onebas.com , an optimised search engine providing a portal to music content freely circulating online.

Shares in Honeydog Limited are valued at $1,600,000 representing a 29.9% holding, unchanged from the prior year. The prior year valuation was used as a starting point for estimation of fair value and the directors have applied consideration to current facts and circumstances in reviewing the May 2022 valuation. Honeydog Limited is the 25% owner of the entity which owns the licence to manufacture and distribute the chemotherapy drug, Temodex, which is used in the treatment of brain tumours.

Shares in Rosedog Limited are valued at $1,600,000 representing a 29.9% holding, unchanged from the prior year. The prior year valuation was used as a starting point for estimation of fair value and the directors have applied consideration to current facts and circumstances in reviewing the May 2022 valuation. Rosedog Limited is the owner of TV Zinos (www.tvzinos.com), a website which offers a number of free-to-view television channels.

 
 
 
              8. INVESTMENTS - continued 
 
              Shares in Bio Vitos Medical Limited are valued at $1,600,000 representing 
              a 24.5% holding, unchanged from the prior year. The prior year valuation 
              was used as a starting point for estimation of fair value and the 
              directors have applied consideration to current facts and circumstances 
              in reviewing the May 2022 valuation. Bio Vitos has a portfolio of 
              over 40 different Omega-3 supplements in addition to its range of 
              collagen products marketed under the "Ocean Skin Lab" brand. During 
              the period, Bio Vitos acquired the licence to market a patented 
              heart drug 'Succifer' (also marketed as 'Inofer'), from Double Bond 
              Pharmaceutical AB. The drug has been demonstrated to improve iron 
              uptake in patients with chronic heart conditions. 
 
              The businesses of all of the above portfolio investments are presently 
              loss-making although their cost bases are low and there is minimal 
              committed future expenditure, meaning that the extent and timing 
              of the Company's further investment in the businesses are highly 
              controllable. The Company and the incumbent management teams of 
              the investee companies will continue to work together with the aim 
              that these businesses become financially self-sustaining and generating 
              surpluses within the short- to medium-term and to crystallise additional 
              capital value for shareholders through strategic, third-party partnerships. 
 
 
 
 
              9. TRADE AND OTHER RECEIVABLES 
                                                   2022    2021 
                                                  $'000   $'000 
               Current: 
               Prepayments and accrued income        43      38 
                                                 ------  ------ 
                                                     43      38 
                                                 ======  ====== 
 
 
 
              10. CASH AND CASH EQUIVALENTS                   2022    2021 
                                $'000   $'000 
               Cash at bank         5       6 
                               ======  ====== 
 
 
              The amounts disclosed in the statement of cash flows in respect 
              of cash and cash equivalents are in respect of the following statement 
              of financial position amounts: 
               Year ended 31 May 2022 
                                             31.5.22   1.6.21 
                                               $'000    $'000 
               Cash and cash equivalents           1        5 
 
               Year ended 31 May 2021 
                                             31.5.21   1.6.20 
                                               $'000    $'000 
               Cash and cash equivalents           5        6 
                                            ========  ======= 
 
 
 
 
 
 
 
 
              11. CALLED UP SHARE CAPITAL 
 
 
               Allotted, called up and 
                fully paid 
               Equity                             Nominal     2022      2021 
                shares 
               Number:              Class:      Value:       $'000     $'000 
 
               3,863,590 (2021: 
                3,863,590)          Ordinary     $1.00       3,802     3,802 
 
                                                             3,802     3,802 
                                                          ========    ====== 
 

The aggregate nominal values of shares include exchange differences arising from the translation of shares at historic rates and the translation at the rate prevailing at the date of the change in functional currency.

                12.      TRADE AND OTHER PAYABLES 
 
                                   2022    2021 
                                  $'000   $'000 
 Current: 
 Trade payables                      46      56 
 Accruals and deferred income        30      31 
                                     76      87 
                                 ======  ====== 
 
                13.       OTHER PAYABLES 
 
                     2022    2021 
                    $'000   $'000 
 Non-current: 
 Other payables     1,237     989 
                    1,237     989 
                   ======  ====== 
 
 
 
 
 
            14. FINANCIAL INSTRUMENTS 
 
            Financial risk management objectives and policies 
 
            Management has adopted certain policies on financial risk management 
            with the objective of: 
 
            i. ensuring that appropriate funding strategies are adopted to meet 
            the Company's short-term and long-term funding requirements taking 
            into consideration the cost of funding, gearing levels and cash 
            flow projections; 
 
            ii. ensuring that appropriate strategies are also adopted to manage 
            related interest and currency risk funding; and 
 
            iii. ensuring that credit risks on receivables are properly managed. 
 
            Financial instrument by category 
 
            The accounting policies for financial instruments have been applied 
            to the line items below: 
 
            Financial assets at fair value through profit or loss 
 
            Financial instruments that are measured subsequent to initial recognition 
            at fair value are grouped into Levels 1 to 3 based on the degree 
            to which the fair value is observable: 
 
            Level 1 fair value measurements are those derived from quoted prices 
            (unadjusted) in active markets for identical assets or liabilities; 
 
            Level 2 fair value measurements for those derived from inputs other 
            than quoted prices included within Level 1 that are observable for 
            the assets or liability, either directly or indirectly; and 
 
            Level 3 fair value measurements are those derived from inputs that 
            are not based on observable market data. 
 
            Unquoted equity investments held at fair value through profit or 
            loss are valued in accordance with the IPEVCV guidelines as follows; 
                                                          2022         2021 
              Investment valuation methodology           $'000        $'000 
             Price of Recent Investment 
              (adjusted for current facts 
              and circumstances) (level 
              3)                                         6,400        6,400 
                                                         6,400        6,400 
                                                      ========      ======= 
 
 
 
            14. FINANCIAL INSTRUMENTS - continued 
 
            IFRS 13 and IFRS 7 requires the directors to consider the impact 
            of changing one or more of the inputs used as part of the valuation 
            process to reasonable possible alternative assumptions. 
 
            The Level 3 valuations listed above include inputs based on non-observable 
            market data as outlined in note 8 above. The Investment Manager 
            has derived a fair value for these investments based on the value 
            of the underlying net assets of the respective investments and 
            / or has considered prospective enterprise values for these investments 
            from the perspective of a market participant. 
 
            The directors have considered a number of reasonable possible alternative 
            assumptions regarding the value of the Level 3 investments. IFRS 
            13 requires an entity to disclose quantitative information about 
            the significant unobservable inputs used. 
 
            A summary of the unobservable inputs, judgements and estimates 
            made in relation to the Level 3 investments is as follows: 
 
            As of the year end, the valuation the Company's minority shareholdings 
            in each its investee companies has been valued on a Price of Recent 
            Investment basis, adjusted for current facts and circumstances 
            which the directors consider represents the best indication of 
            the fair value at the year end. All five of these businesses are 
            presently loss-making although their cost bases are low and there 
            is minimal committed future expenditure, meaning that the extent 
            and timing of the Company's further investment in the businesses 
            are highly controllable. 
 
            However, each business operates in a competitive market place and 
            there can be no guarantee that any of the investee companies will 
            ultimately be successful and that the future carrying value of 
            these companies will not need to be impaired. In the worst-case 
            scenario of any one investment having to be fully impaired, this 
            would result in a decrease of valuation of the investment of $1,600,000. 
 
 
 
            14 . FINANCIAL INSTRUMENTS - continued 
 
            The valuation method applied to each equity investment is that which 
            is considered most appropriate with regard to the stage of development 
            of the investee business and the IPEVCV guidelines. 
 
            All other financial instruments, including cash and cash equivalents, 
            trade and other receivables, trade and other payables and loans 
            and borrowings, are measured at amortised cost. 
 
            Due to their short-term nature, the carrying values of cash and 
            cash equivalents, trade and other receivables, trade and other payables 
            and loans and borrowings approximates their fair value. 
 
            Credit risk 
 
            The Company's credit risk is primarily attributable to other receivables. 
            Management has a credit policy in place and the exposure to credit 
            risks is monitored on an ongoing basis. In respect of other receivables, 
            individual credit evaluations are performed whenever necessary. 
            The Company's maximum exposure to credit risk is represented by 
            loans, both those held as unquoted investments and included in other 
            receivables, and cash balances. The Company monitors the financial 
            position of borrowing entities on an ongoing basis and is satisfied 
            with the quality of the debt. Investment of surplus cash balances 
            are reviewed on an annual basis by the Company and it is satisfied 
            with the choice of institution. The directors have assessed the 
            amounts owed to connected parties for impairment in accordance with 
            IFRS 9 and concluded that there is no material impact. 
 
            Interest rate risk 
 
            The Company currently operates with positive cash and cash equivalents 
            as a result of issuing share capital in anticipation of future funding 
            requirements. As the Company has no borrowings from the bank and 
            the amount of deposits in the bank are not significant, the exposure 
            to interest rate risk is not significant to the Company. 
 
            Liquidity risk 
 
            The Company manages its liquidity requirements by the use of both 
            short-term and long-term cash flow forecasts. The Company's policy 
            to ensure facilities are available as required is to issue equity 
            share capital in accordance with agreed settlement terms with vendors 
            or professional firms, and are typically due within one year unless 
            otherwise stated. 
 
            The Company maintains minimal cash reserves, however in addition 
            to the cash on the Company's statement of financial position, sufficient 
            cash is available to the Company via credit facilities to ensure 
            it is able to meet its liabilities as they fall due. 
 
   14 .     FINANCIAL INSTRUMENTS - continued 

The table below summarises the maturity profile of the Company's financial liabilities based on contractual discounted payments.

 
                                     Less      3 to 
                            On       than       12     More than 
                          Demand   3 months   months   12 Months   Total 
 Year ended 31 
  May 2022                $'000     $'000     $'000      $'000     $'000 
 
 Trade payables               46          -        -           -      46 
 Other payables                -          -        -       1,237   1,237 
 Accruals and deferred 
  income                      30          -        -           -      30 
                              76          -        -       1,237   1,313 
                         -------  ---------  -------  ----------  ------ 
 
 Year ended 31 May 
  2021 
 Trade payables               56          -        -           -      56 
 Other payables                -          -        -         989     989 
 Accruals and deferred 
  income                      31          -        -           -      31 
                              87          -        -         989   1,076 
                         -------  ---------  -------  ----------  ------ 
 

Price risks

The Company's securities are susceptible to price risk arising from uncertainties about future value of its investments. This price risk is the risk that the fair value of future cash flows will fluctuate because of changes in market prices, whether those changes are caused by factors specific to the individual investment or financial instrument or its holder or factors affecting all similar financial instruments or investments traded in the market.

During the year under review, the Company did not hedge against movements in the value of its investments. A 10% increase/decrease in the fair value of investments would result in a $640,000 (2021: $640,000 increase/decrease in the net asset value).

While investments in companies whose business operations are based in emerging markets may offer the opportunity for significant capital gains, such investments also involve a degree of business and financial risk, in particular for unquoted investments.

Generally, the Company is prepared to hold unquoted investments for a medium to long time frame, in particular if an admission to trading on a stock exchange has not yet been planned. Sale of securities in unquoted investments may result in a discount to the book value.

Currency risks

The Company is exposed to foreign currency risk on its investments held at fair value and adverse movements in foreign exchange rates will reduce the values of these investments. There is no systematic hedging in foreign currencies against such possible losses on translation/realisation.

Foreign exchange volatility is significantly reduced following the transition to US Dollar as the Company's currency exposures are now more closely matched to its functional and reporting currency. The Company's exposure to other foreign currency changes is not deemed to be material as the Company's investments are US Dollar based.

   14.     FINANCIAL INSTRUMENTS - continued 

Capital management

The Company's financial strategy is to utilise its resources to further grow its portfolio. The Company keeps investors and the market informed of its progress with its portfolio through periodic announcements and raises additional equity finance at appropriate times. The Company regularly reviews and manages its capital structure for the portfolio companies to maintain a balance between the higher shareholder returns that might be possible with certain levels of borrowing for the portfolio and the advantages and security afforded by a sound capital position, and makes adjustments to the capital structure of the portfolio in the light of changes in economic conditions. Although the Company has utilised loans from shareholders to acquire investments, it is the Company's policy as far as possible to finance its investing activities with equity and not to have gearing in its portfolio.

At the statement of financial position date the capital structure of the Company consisted of cash and cash equivalents and equity comprising issued capital and reserves.

The table below sets out the Company's classification of each class of financial assets/liabilities, their fair values (where appropriate) and under which valuation method they are valued:

 
                                                                                           Total carrying 
                                                                                               amount and 
                                                  Level           Level           Level              Fair 
                                                      1               2               3 
                                  Notes           $'000           $'000           $'000             Value 
                                                                                                    $'000 
 31 May 2022 
 Loans and receivables 
 Trade and other receivables       9                  -               -              43                43 
 Cash and cash equivalents        10                  1               -               -                 1 
                                              ---------       ---------       ---------  ---------------- 
                                                      1               -              43                44 
 Liabilities at amortised 
  cost 
                                              ---------       ---------       ---------  ---------------- 
 Trade and other payables        12&13                -               -         (1,313)           (1,313) 
                                              ---------       ---------       ---------  ---------------- 
 
 Fair value through 
  profit and loss 
  Investments                       8                 -               -           6,400             6,400 
                                                      1               -           5,130             5,131 
                                              ---------       ---------       ---------  ---------------- 
 31 May 2021 
 Loans and receivables 
 Trade and other receivables       9                  -               -              38                38 
 Cash and cash equivalents        10                  5               -               -                 5 
                                              ---------       ---------       ---------  ---------------- 
                                                      5               -              38                43 
 Liabilities at amortised 
  cost 
                                              ---------  --------------       ---------  ---------------- 
 Trade and other payables        12&13                -               -         (1,076)           (1,076) 
 
   Fair value through 
   profit and loss 
   Investments                      8                 -               -           6,400             6,400 
                                                      5               -           5,362             5,367 
                                              ---------  --------------       ---------  ---------------- 
 
 
   15.     RELATED PARTY DISCLOSURES 

During the year, Craven Industrial Holdings Plc made loans to and incurred costs on behalf of the Company.

Loan interest charged for the year at 5% amounted to $55,615 (2021: GBPnil).

At the year end, a balance of $1,236,190 (2021: GBP989,320) was due from the Company to Craven Industrial Holdings Plc.

Despite the common director in Mr M J Pajak, the board of Craven House Capital Plc do not believe that Craven House Capital Plc or Craven Industrial Holdings Plc are able to exert control or influence over each other and neither are accustomed to act in accordance with instructions from the other.

Directors and key management

All key management personnel are directors and appropriate disclosure with respect to them is made in note 3 of the financial statements. There are no other contracts of significance in which any director has or had during the year a material interest.

   16.      ULTIMATE CONTROLLING PARTY 

The directors consider that there is no ultimate controlling party.

   17.       EVENTS AFTER THE REPORTING PERIOD 

On 15 November 2022, the Company announced that the management of Garimon had transferred out the domain name www.onebas.com to a separate entity, Stormfjord Ltd and that Stormfjord had raised $0.52m in cash at a valuation of $5m. Craven House did not participate in the fundraising and as a result, its shareholding in Stormfjord is 26.2%.

The www.onebas.com domain was transferred out of Garimon in order to facilitate further fundraising activity focused on the domain. Craven House continues to own 29.9% of Garimon which owns the domain www.magazinos.com .

The Annual Results for year ended 31 May 2022 will be available to download from the Company's website at: http://www.cravenhousecapital.com

Ends

For further information please contact:

 
 Craven House Capital Plc            Tel: 0203 286 8130 
  Mark Pajak 
  www.Cravenhousecapital.com 
 SI Capital                          Tel: 01483 413500 
  Broker 
  Nick Emerson 
  www.sicapital.co.uk 
 
   SPARK Advisory Partners Limited     Tel: 0203 368 3550 
   Nominated Adviser 
   Matt Davis 
   www.Sparkadvisorypartners.com 
 

About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.

, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

FR UWUWRUSUAUAA

(END) Dow Jones Newswires

November 29, 2022 02:00 ET (07:00 GMT)

Craven House Capital (LSE:CRV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Craven House Capital.
Craven House Capital (LSE:CRV)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Craven House Capital.